NCT06109207 2024-07-23Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell CarcinomasWest China HospitalPhase 1 Recruiting6 enrolled
NCT06199271 2024-01-22Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell CarcinomaSichuan UniversityPhase 2 Not yet recruiting30 enrolled